Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir

Antiviral Therapy

Volumn 12, Issue 1, 2007, Pages 31-39

  Gérard, Laurence ^a   Chazallon, Corine ^a   Taburet, Anne Marie ^b   Girard, Pierre Marie ^c   Aboulker, Jean Pierre ^a   Piketty, Christophe ^d  

^a INSERM   (France)

^b BICÊTRE HOSPITAL   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; COTRIMOXAZOLE; DIDANOSINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; VIRUS RNA; ZALCITABINE;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

ADENINE; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CREATININE; FEMALE; FRANCE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; OLIGOPEPTIDES; PHOSPHONIC ACIDS; PROGNOSIS; PROSPECTIVE STUDIES; PYRIDINES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; TREATMENT OUTCOME;

EID: 33847416252     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48 week, randomized, double-blind study. AIDS 2002; 16:1257-1263.
2. Squires K, Pozniak AL, Pierone G, Jr., et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med 2003; 139:313-320.
3. Tarantal AF, Marthas ML, Shaw JP, Cundy K, Bischofberger N. Administration of 9 [2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:323-333.
4. Van Rompay KK, Brignolo LL, Meyer DJ, et al. Biological effects of short-term or prolonged administration of 9 [2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 2004; 48:1469-1487.
5. Viread [tenofovir disoproxil fumarate]. Package insert. 2005. Gilead Sciences, Foster City, CA, USA.
6. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-260.
7. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3 year randomized trial. JAMA 2004; 292:191-201.
8. Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004; 35:269-273.
9. Izzedine H, Isnard-Bagnis C, Hulot JS, et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 2004; 18:1074-1076.
10. Barrios A, Garcia-Benayas T, Gonzalez-Lahoz J, Soriano V. Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS 2004; 18:960-963.
11. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36:1070-1073.
12. Creput C, Gonzalez-Canali G, Hill G, Piketty C, Kazatchkine M, Nochy D. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS 2003; 17:935-937.
13. Tenofovir DF expanded access. AIDS Treat News 2001; 360:1.
14. Izzedine H, Hulot JS, Vittecoq D, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 2005; 20:743-746.
15. Piketty C, Gérard L, Chazallon C, et al. Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial. Antivir Ther 2006; 11:213-221.
16. Cockroft D, Gault M. Prediction of creatinine clearance form serum ceratinine. Nephron 1976; 16:31-41.
17. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40:1559-1585.
18. Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48:2091-2096.
19. Hazra R, Balis FM, Tullio AN, et al. Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 2004; 48:124-129.
20. Viread [tenofovir disoproxil fumarate]. Package insert. 2001. Gilead Sciences, Foster City, CA, USA.
21. Antoniou T, Raboud J, Chirhin S, et al. Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. HIV Med 2005; 6:284-290.
22. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 40:1194-1198.
23. Daugas E, Rougier JP, Hill G. HAART-related nephropathies in HIV-infected patients. Kidney Int 2005; 67:393-403.
24. Rollot F, Nazal EM, Chauvelot-Moachon L, et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin Infect Dis 2003; 37:e174-176.
25. Miller DS. Nucleoside phosphonate interactions with multiple organic anion transporters in renal proximal tubule. J Pharmacol Exp Ther 2001;299:567-574.
26. Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet 1999; 36:127-143.
27. Gutmann H, Fricker G, Drewe J, Toeroek M, Miller DS. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 1999; 56:383-389.
28. Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 2005; 45:804-817.
29. Ray AS, Cihlar T, Robinson KL, et al. Mechanism of active tubular secretion of tenofovir and potential for a renal drug-drug interaction with HIV protease inhibitors. 7th International Workshop on Clinical Pharmacology of HIV Therapy. Lisbon, Portugal. April 20-22, 2006. Abstract 49.
30. Tanji N, Tanji K, Kambham N, Markowitz GS, Bell A, D'Agati V D. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol 2001; 32:734-740.
31. Saumoy M, Vidal F, Peraire J, et al. Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity? AIDS 2004; 18:1741-1742.
32. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002; 46:716-723.
33. Pecora Fulco P, Kirian MA. Effect of tenofovir on didanosine absorption in patients with HIV. Ann Pharmacother 2003; 37:1325-1328.
34. Côté HCF, Magil AB, Harris M, et al. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy. Antivir Ther 2006; 11:79-86.
35. Ray AS, Olson L, Fridland A. Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob Agents Chemother 2004; 48:1089-1095.
36. Vincent I, Barrail A, Piketty C, et al. Pharmacokinetic Parameters of Tenofovir when combined with Atazanavir/Ritonavir in HIV Infected Patients with Multiple Treatment Failures: a Substudy of Puzzle2- ANRS 107 Trial. 6th International Workshop on Clinical Pharmacology of HIV Therapy. 28-30 April 2005. Québec City, Quebec, Canada. Session 4.
37. Kruse G, Stocker H, Breske A, et al. Trough levels of six different atazanavir regimens in HIV-infected patients. 5th International Workshop on Clinical Pharmacology of HIV Therapy. Rome, Italy. 1-3 April 2004. Session 6.
38. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004; 43:595-612.
39. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001; 45:2733-2739.
40. Pruvost A, Negredo E, Benech H, et al. Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2005; 49:1907-1914.
41. Hawkins T, Veikley W, St Claire RL, 3rd, Guyer B, Clark N, Kearney BP. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr 2005; 39:406-411.
42. Back DJ, Burger DM, Flexner CW, Gerber JG. The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosing. J Acquir Immune Defic Syndr 2005; 39 Suppl 1:51-23.
43. Gallant JE, Parish MA, Keruly JC, Moore RD. Tenofovir and changes in renal function: reply to Gupta [letter]. Clin Infect Dis 2005; 41:571.